轻松千山
Lv5
1258 积分
2024-05-27 加入
-
The SLC6A15-SLC6A20 Neutral Amino Acid Transporter Subfamily: Functions, Diseases, and Their Therapeutic Relevance
5天前
已完结
-
The pharmacological basis for nonpeptide agonism of the GLP-1 receptor by orforglipron
23天前
已完结
-
Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management
1个月前
已完结
-
A New Long-acting Liposomal Topical Antifungal Formula: Human Clinical Study
1个月前
已完结
-
Chronic Kidney Disease - Competitive landscape, 2023
1个月前
已完结
-
Aristolochic acid-induced nephropathy is attenuated in mice lacking the neutral amino acid transporter B0AT1 (Slc6a19)
1个月前
已完结
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial
2个月前
已完结
-
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
2个月前
已完结
-
Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial
2个月前
已完结
-
Thyroid eye disease (Graves' orbitopathy): clinical presentation, epidemiology, pathogenesis, and management
3个月前
已完结